Indian Pharma

India to add 50 new pharma greenfield plants under PLI scheme: Pharma Secy

He stated that the Indian meditech industry also exported more than the country imported in the surgical and consumable space

World Pharmacist Day 2024: Date, History, significance, wishes and quotes

Every year on September 25, 2023, World Pharmacist Day is observed as a special day to honour and acknowledge pharmacists for their enormous contributions to enhancing world health

Indian pharma firms seek govt tax reliefs, incentives to spur innovation

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

Indian pharma cos make versions of Wegovy to get in on weight-loss windfall

Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026

Indian drug firms look for new opportunities in Saudi Arabia pharma market

Indian drug firms sense opportunity to increase presence in $8.9 bn Saudi market

Trade generics growth to dent value expansion of domestic drug market

Jan Aushadhi and trade generics together constitute 20-22% of pharma market volumes

USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

The US health regulator has pulled up Intas Pharmaceuticals for manufacturing lapses, including violation of current good manufacturing practice (CGMP) regulation, at its Ahmedabad-based plant. In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. The USFDA inspected the facility from May 1-12, 2023. "This warning letter summarises significant violations of CGMP regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," it noted. In the warning letter, the health regulator pointed out the company "failed to exercise its responsibility to ensure drug products manufactured

Indian pharma industry can grow to $450 bn by 2047: EY-OPPI report

The report underlines the need for collaboration and alignment between the industry, academia and government to advance research and innovation capabilities

Lupin announces launch of world's first FDC drug for chronic lung disease

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate, and Glycopyrronium Bromide for the long-term management and treatment of moderate to severe COPD

Ryzneuta for chemotherapy-induced neutropenia receives USFDA approval

Acrotech Biopharma is preparing to commercialise Ryzneuta in the United States in the near future

India must save the reputation of its pharma industry

When both our trading partners and our own doctors raise questions about the quality of medicines we make, what is the government doing to assuage these valid concerns?

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

The delayed season not only affected anti-infectives but also related sub-therapies such as respiratory, cough and cold, gastro, and vitamins, says Juneja

Govt mulling guidelines for OTC medicines; move to reduce burden on doctors

Industry players present at the event highlighted that the OTC market offers a major business opportunity, but it needs transparent and clear regulations

Biocon, Juno Pharma ink pact for commercialisation of Liraglutide in Canada

Under the agreement's terms, Biocon will be responsible for obtaining regulatory approvals for Liraglutide and will subsequently manage the manufacturing and distribution of the product within Canada

Cytiva opens new manufacturing facility and experience center in Pune

The newly unveiled manufacturing facility in Pune will produce bioprocessing equipment, including tangential flow, virus filtration, and inactivation systems

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Indian pharma exports to Iran have declined from $205.1 million in FY20 to $59.14 million in FY23. Iran's rupee reserves have depleted as India ceased oil imports from the country in mid-2019

Cipla's US subsidiary InvaGen gets 5 inspectional observations from USFDA

The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) for a site transfer product within InvaGen

Generic medicines: Indian pharma market is at crossroads of systemic shift

Companies must start preparing their business models to adjust to the reality of the shift to medical practitioners prescribing only generic molecule names

Fierce competition among new drug brands for share of India market

The competitive intensity is high between brands, at a time when volume growth in the domestic pharma market is on a slow lane

All provisions of medical devices rules to come into force from Oct 1: DCGI

Medical devices of all four categories (A, B, C, and D) will be brought under the regulation by October 1 and as of now only two groups (A and B) are being regulated, Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi said on Wednesday. Speaking to reporters on the sidelines of the 9th International Pharmaceutical Exhibition (iPHEX) being organised by the Pharmaceuticals Exports Promotion Council (Pharmexcil) here, Raghuvanshi said the regulations would ensure quality in the production of medical devices. "In the medical devices, we are categorising into four groups. Two groups (A and B) are already notified. C and D are left which will happen from October 1," he said. The Union Cabinet on April 26 approved the National Medical Devices Policy, 2023 to give a thrust to the sector with quality controls. The market size of the medical devices sector in India is estimated to be USD 11 billion (approximately Rs 90,000 crore) in 2020 and its share in the global medical devi